Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.38 |
| ▸ | TP53 | P04637 | 7/20 | 0.38 |
| ▸ | RAD52 | P43351 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.36 |
| ▸ | UBE2N | P61088 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
| ▸ | WHR1 | P49842 | 2/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6469547 | 0.91 | MAPT (0.38) | MAPTTP53RAD52POLBMEN1 | |
| SCHEMBL6470555 | 0.88 | KDM4E (0.44) | MAPTTP53POLBMEN1KMT2A | |
| SCHEMBL6468688 | 0.88 | KDM1A (0.36) | MAPTTP53RAD52POLBMEN1 | |
| SCHEMBL6465687 | 0.86 | KMT2A (0.31) | TP53RAD52POLBMEN1KMT2A | |
| SCHEMBL6466111 | 0.86 | ABCG2 (0.41) | MAPTTP53RAD52POLBMEN1 | |
| SCHEMBL6467851 | 0.85 | MAPT (0.36) | MAPTTP53RAD52POLBMEN1 | |
| Trifluoroacetic Acid SCHEMBL6469598 | 0.84 | MAPT (0.41) | MAPTTP53RAD52POLBMEN1 | |
| SCHEMBL6467461 | 0.83 | KDM4E (0.44) | MAPTTP53POLBMEN1KMT2A | |
| SCHEMBL6469501 | 0.82 | ABCG2 (0.38) | MAPTTP53RAD52POLBMEN1 | |
| SCHEMBL6467193 | 0.82 | ABCG2 (0.40) | MAPTTP53RAD52POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124562-A1 | Bis-quinazoline compounds for the treatment of bacterial infections | REPLIDYNE, INC. | 2005-06-09 | — | — | US | claimed |
| WO-2005030131-A2 | BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | REPLIDYNE, INC (US) | 2005-04-07 | — | — | WO | claimed |
| US-20050124562-A1 | Bis-quinazoline compounds for the treatment of bacterial infections | REPLIDYNE, INC. | 2005-06-09 | — | — | US | disclosed |
| WO-2005030131-A2 | BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | REPLIDYNE, INC (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124562-A1 | Bis-quinazoline compounds for the treatment of bacterial infections | POLI, POLK, POLB | MAPT 3552/4885TP53 1339/4885RAD52 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.